Angion Biomedica Nears End of Clinical Trials for Organ-Repairing Molecule

Repairing a damaged organ in order to allow an individual to have a healthier life, as well as a greater quality of life, could soon be a reality as New York-based Angion Biomedica Corp.moves toward completing clinical trials of its lead asset.